Abstract

Purpose To investigate the effect of rapamycin (Rapa) on growth or regression of Walker tumor used alone or in combination with CsA and MMF. Methods and results Wistar rats received water (control) or Rapa or CsA 1 day before and daily after tumor inoculation. On day 10, tumor volume (TV) was smaller among Rapa (6.8 ± 2.7 cm 3) versus control (14.9 ± 4.2 cm 3, P < .001) or CsA (13.9 ± 3.0 cm 3, P < .0001) treatment groups. Tumor growth was greatly inhibited (TI) by Rapa (−49.3%). Tumor weight (TW) was significantly ( P ≤ .001) lower in Rapa (3.7 ± 1.2 g) versus CsA (8.8 ± 2.1 g) or control (7.3 ± 2.0 g) animals. An additional set of rats received water or Rapa or CsA + Rapa, or MMF + Rapa 1 day before tumor inoculation. On day 10, TV and TW were lower among Rapa (3.8 ± 1.5 cm 3) and Rapa + CsA (3.1 ± 1.2 cm 3) and Rapa + MMF (4.6 ± 2.7 cm 3) groups compared with controls (10.9 ± 3.8 cm 3, P < .0001). TI was −52.1% in Rapa, −68.5% in Rapa + CsA, and −63% in Rapa + MMF. A further set of rats received either water or Rapa on the day 4 after tumor inoculation. On day 10, tumor growth and TW among the Rapa and control groups were similar. Conclusion Rapamycin greatly inhibited tumor growth when used alone or with CsA or MMF, but did not produce an effect on a well-established Walker sarcoma.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.